Investigating the effect of liposomal membrane fluidity and antibody lateral mobility on endothelial cell targeting

Abstract

Atherosclerosis is initiated by the adhesion of leukocytes to the endothelial surface of arteries followed by migration beneath the intima. Current therapies to combat atherosclerotic plaque, such as statins or antihypertensive drugs, treat atherosclerosis indirectly; they do not specifically target inflamed vasculature or improve the vascular condition. Few studies have focused on antibody mobility or membrane fluidity as an approach to improve drug delivery vehicle binding and uptake.